6月1日，科伦博泰生物盘中上涨4.5%，报466.8港元，成交额8166.8万港元。
消息面上，科伦博泰生物被列为6月十大金股之一，叠加此前ASCO年会重磅临床数据持续催化。公司核心产品TROP2 ADC药物sac-TMT已启动17项三期临床研究，野村此前上调其目标价至544.42港元并维持"买入"评级，认为该药物在PD-L1阳性非小细胞肺癌III期试验中PFS风险比达0.35，系全球首个在该适应症中显示PFS改善的ADC药物。市场预计其海外销售峰值可达150亿美元，有望于明年实现盈利。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.